

EDWIN B. ABRAMSON, M.D.
1001 W. ROCKLAND STREET
PHILADELPHIA, PA. 19141

January 26, 1969


Herbert L. Ley, Jr., M.D.
Commissioner of Food & Drugs
Department of Health, Education & Welfare
Washington, D.C. 20204

Dear Dr. Ley:

The NAS/NRC panel's report on Mysteclin-F indicates that they are not aware of evidence of proved efficacy in the prevention of disease due to monilia organisms, although suppression of growth of monilia may be accomplished.

However, my informed medical judgment as supported by widespread medical opinion is that spread of intestinal candida to cause candidiasis is a risk which in the indicated conditions should be considered in using antibiotic therapy. The combination contained in Mysteclin-F in my experience is convenient, useful, effective and of definite value in the care of my patients.

Sincerely,


Edwin B. Abramson, M.D.

EEA/pmf